Cytokine gene therapy for malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 2, Issue 4, 2007, Pages 265-267

  Vachani, Anil ^a,b   Sterman, Daniel H ^a   Albelda, Steven M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE SYSTEM; METASTASIS; NONHUMAN; PLEURA CAVITY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SHORT SURVEY; TUMOR GROWTH; CANCER STAGING; FEMALE; INTRALESIONAL DRUG ADMINISTRATION; MALE; MESOTHELIOMA; METHODOLOGY; MORTALITY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PLEURA TUMOR; PROGNOSIS; REVIEW; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE I; CYTOKINES; FEMALE; GENE THERAPY; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34247868982     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000263706.23579.35     Document Type: Article

References (28)

1. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997;63:334-338.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
3. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model. J Interferon Cytokine Res 1995;15:213-223.
4. Fitzpatrick DR, Manning LS, Musk AW, et al. Potential for cytokine therapy of malignant mesothelioma. Cancer Treat Rev 1995;21:273-288.
5. Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 1998;83:2099-2104.
6. Boutin C, Viallat JR, Van Zandwijk N, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991;67:2033-2037.
7. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994;74:2460-2467.
8. Goey SH, Eggermont AM, Punt CJ, et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995;72:1283-1288.
9. Robinson BW, Bowman R, Manning LS, et al. Interleukin-2 and lymphokine-activated killer cells in malignant mesothelioma. Eur Respir Rev 1993;3:220-222.
10. Christmas TI, Manning LS, Garlepp MJ, et al. Effect of interferon-alpha 2a on malignant mesothelioma. J Interferon Res 1993;13:9-12.
11. Lengyel P. Biochemistry of interferons and their actions. Annu Rev Biochem 1982;51:251-282.
12. Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 1998;10:383-390.
13. Qin XQ, Runkel L, Deck C, et al. Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 1997;17:355-367.
14. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489-2499.
15. Sen GC, Lengyel P. The interferon system: a bird's eye view of its biochemistry. J Biol Chem 1992;267:5017-5020.
16. Brem H, Gresser I, Grosfeld J, et al. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 1993;28:1253-1257.
17. Sturzebecher S, Maibauer R, Heuner A, et al. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. J Interferon Cytokine Res 1999;19:1257-1264.
18. Ravandi F, Estrov Z, Kurzrock R, et al. A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Clin Cancer Res 1999;5:3990-3998.
19. Yagi K, Hayashi Y, Ishida N, et al. Interferon-beta endogenously produced by intratumoral injection of cationic liposome-encapsulated gene: cytocidal effect on glioma transplanted into nude mouse brain. Biochem Mol Biol Int 1994;32:167-171.
20. Natsume A, Tsujimura K, Mizuno M, et al. IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 2000;47:117-124.
21. Natsume A, Mizuno M, Ryuke Y, et al. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 1999;6:1626-1633.
22. Lu W, Fidler IJ, Dong Z. Eradication of primary murine fibrosarcomas and induction of systemic immunity by adenovirus-mediated interferon beta gene therapy. Cancer Res 1999;59:5202-5208.
23. Odaka M, Sterman DH, Wiewrodt R, et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 2001;61:6201-6212.
24. Odaka M, Wiewrodt R, DeLong P, et al. Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. Mol Ther 2002;6:210-218.
25. Wilderman MJ, Kim S, Gillespie CT, et al. Blockade of TNF-alpha decreases both inflammation and efficacy of intrapulmonary Ad.IFNbeta immunotherapy in an orthotopic model of bronchogenic lung cancer. Mol Ther 2006;13:910-917.
26. Sterman DH, Gillespie CT, Carroll RG, et al. Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat Clin Pract Oncol 2006;3:633-639.
27. Kruklitis RJ, Singhal S, Delong P, et al. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004;127:123-130.
28. DeLong P, Tanaka T, Kruklitis R, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003;63:7845-7852.